Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
TFX's Cash to Debt is ranked lower than
52% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. TFX: 0.22 )
TFX' s 10-Year Cash to Debt Range
Min: 0.05   Max: 0.93
Current: 0.22

0.05
0.93
Equity to Asset 0.49
TFX's Equity to Asset is ranked higher than
56% of the 373 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. TFX: 0.49 )
TFX' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.53
Current: 0.49

0.32
0.53
Interest Coverage 4.10
TFX's Interest Coverage is ranked lower than
56% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 81.00 vs. TFX: 4.10 )
TFX' s 10-Year Interest Coverage Range
Min: 2.57   Max: 9.07
Current: 4.1

2.57
9.07
F-Score: 7
Z-Score: 1.97
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 13.75
TFX's Operating margin (%) is ranked higher than
85% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. TFX: 13.75 )
TFX' s 10-Year Operating margin (%) Range
Min: -6.28   Max: 15.38
Current: 13.75

-6.28
15.38
Net-margin (%) 8.89
TFX's Net-margin (%) is ranked higher than
84% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. TFX: 8.89 )
TFX' s 10-Year Net-margin (%) Range
Min: -12.25   Max: 21.66
Current: 8.89

-12.25
21.66
ROE (%) 7.88
TFX's ROE (%) is ranked higher than
79% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 5.57 vs. TFX: 7.88 )
TFX' s 10-Year ROE (%) Range
Min: -10.68   Max: 19.17
Current: 7.88

-10.68
19.17
ROA (%) 3.58
TFX's ROA (%) is ranked higher than
75% of the 392 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. TFX: 3.58 )
TFX' s 10-Year ROA (%) Range
Min: -5.08   Max: 8.24
Current: 3.58

-5.08
8.24
ROC (Joel Greenblatt) (%) 28.60
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 12.89 vs. TFX: 28.60 )
TFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12.81   Max: 42.11
Current: 28.6

-12.81
42.11
Revenue Growth (%) -4.60
TFX's Revenue Growth (%) is ranked higher than
59% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. TFX: -4.60 )
TFX' s 10-Year Revenue Growth (%) Range
Min: -15.6   Max: 17.3
Current: -4.6

-15.6
17.3
EBITDA Growth (%) -2.10
TFX's EBITDA Growth (%) is ranked higher than
77% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.90 vs. TFX: -2.10 )
TFX' s 10-Year EBITDA Growth (%) Range
Min: -13.7   Max: 18.6
Current: -2.1

-13.7
18.6
EPS Growth (%) 16.10
TFX's EPS Growth (%) is ranked higher than
86% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. TFX: 16.10 )
TFX' s 10-Year EPS Growth (%) Range
Min: -17.4   Max: 16.1
Current: 16.1

-17.4
16.1
» TFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TFX Guru Trades in Q3 2013

Manning & Napier Advisors, Inc 1,214,740 sh (New)
Third Avenue Management 557,733 sh (+14.72%)
Robert Olstein 81,000 sh (+8%)
Chuck Royce 369,700 sh (unchged)
David Dreman Sold Out
Jim Simons Sold Out
Murray Stahl 6,701 sh (-6.94%)
John Keeley 4,700 sh (-86.51%)
» More
Q4 2013

TFX Guru Trades in Q4 2013

Jim Simons 106,800 sh (New)
Steven Cohen 13,271 sh (New)
Murray Stahl 6,729 sh (+0.42%)
Chuck Royce 369,700 sh (unchged)
John Keeley 4,700 sh (unchged)
Manning & Napier Advisors, Inc 1,200,192 sh (-1.2%)
Robert Olstein 69,000 sh (-14.81%)
Third Avenue Management 369,692 sh (-33.72%)
» More
Q1 2014

TFX Guru Trades in Q1 2014

Paul Tudor Jones 2,900 sh (New)
Joel Greenblatt 11,603 sh (New)
Jim Simons 329,868 sh (+208.87%)
Third Avenue Management 369,692 sh (unchged)
Murray Stahl 6,679 sh (-0.74%)
Robert Olstein 65,000 sh (-5.8%)
Manning & Napier Advisors, Inc 1,038,814 sh (-13.45%)
Chuck Royce 309,700 sh (-16.23%)
John Keeley 3,820 sh (-18.72%)
Steven Cohen 4,300 sh (-67.6%)
» More
Q2 2014

TFX Guru Trades in Q2 2014

Joel Greenblatt 17,351 sh (+49.54%)
Jim Simons 375,400 sh (+13.8%)
John Keeley 3,820 sh (unchged)
Murray Stahl 6,679 sh (unchged)
Chuck Royce 309,700 sh (unchged)
Robert Olstein 63,000 sh (-3.08%)
Paul Tudor Jones 2,800 sh (-3.45%)
Third Avenue Management 270,465 sh (-26.84%)
Manning & Napier Advisors, Inc 2,190 sh (-99.79%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 49.54%0.01%$100.44 - $108.69 $ 109.484%17351
Joel Greenblatt 2014-03-31 New Buy0.02%$90.94 - $106.1 $ 109.4812%11603
David Dreman 2013-09-30 Sold Out 0.09%$75.01 - $82.07 $ 109.4839%0
John Keeley 2013-09-30 Reduce -86.51%0.05%$75.01 - $82.07 $ 109.4839%4700
David Dreman 2013-03-31 Reduce -90.77%0.84%$71.31 - $84.51 $ 109.4841%41925
John Keeley 2012-09-30 New Buy0.05%$60.55 - $70.62 $ 109.4870%33250
Joel Greenblatt 2012-03-31 Sold Out 0.08%$58.01 - $63.56 $ 109.4892%0
Joel Greenblatt 2011-09-30 Reduce -64.36%0.15%$49.51 - $63.14 $ 109.4893%9888
Joel Greenblatt 2011-06-30 Add 140.23%0.14%$57.82 - $63.81 $ 109.4880%27742
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.10
TFX's P/E(ttm) is ranked higher than
79% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 78.90 vs. TFX: 30.10 )
TFX' s 10-Year P/E(ttm) Range
Min: 4.99   Max: 258.41
Current: 30.1

4.99
258.41
P/B 2.30
TFX's P/B is ranked higher than
72% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. TFX: 2.30 )
TFX' s 10-Year P/B Range
Min: 1.04   Max: 2.54
Current: 2.3

1.04
2.54
P/S 2.80
TFX's P/S is ranked higher than
64% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. TFX: 2.80 )
TFX' s 10-Year P/S Range
Min: 0.68   Max: 2.8
Current: 2.8

0.68
2.8
PFCF 21.20
TFX's PFCF is ranked higher than
90% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 21.20 )
TFX' s 10-Year PFCF Range
Min: 5.93   Max: 51.16
Current: 21.2

5.93
51.16
EV-to-EBIT 21.12
TFX's EV-to-EBIT is ranked higher than
83% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 57.01 vs. TFX: 21.12 )
TFX' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 23.7
Current: 21.12

8.3
23.7
Shiller P/E 26.70
TFX's Shiller P/E is ranked higher than
86% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 26.70 )
TFX' s 10-Year Shiller P/E Range
Min: 10.3   Max: 27.44
Current: 26.7

10.3
27.44
Current Ratio 1.60
TFX's Current Ratio is ranked higher than
52% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. TFX: 1.60 )
TFX' s 10-Year Current Ratio Range
Min: 1.46   Max: 5.2
Current: 1.6

1.46
5.2
Quick Ratio 1.05
TFX's Quick Ratio is ranked lower than
51% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. TFX: 1.05 )
TFX' s 10-Year Quick Ratio Range
Min: 0.86   Max: 4.01
Current: 1.05

0.86
4.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.20
TFX's Dividend Yield is ranked higher than
53% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 1.17 vs. TFX: 1.20 )
TFX' s 10-Year Dividend Yield Range
Min: 1.25   Max: 3.48
Current: 1.2

1.25
3.48
Dividend Payout 0.37
TFX's Dividend Payout is ranked higher than
86% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 0.37 )
TFX' s 10-Year Dividend Payout Range
Min: 0.06   Max: 2.13
Current: 0.37

0.06
2.13
Yield on cost (5-Year) 1.20
TFX's Yield on cost (5-Year) is ranked higher than
51% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 1.23 vs. TFX: 1.20 )
TFX' s 10-Year Yield on cost (5-Year) Range
Min: 1.25   Max: 3.48
Current: 1.2

1.25
3.48
Share Buyback Rate -2.70
TFX's Share Buyback Rate is ranked higher than
71% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -0.90 vs. TFX: -2.70 )
TFX' s 10-Year Share Buyback Rate Range
Min: 1   Max: -2.7
Current: -2.7

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.70
TFX's Price/DCF (Projected) is ranked higher than
88% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. TFX: 1.70 )
TFX' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 2.88
Current: 1.7

0.48
2.88
Price/Median PS Value 2.10
TFX's Price/Median PS Value is ranked higher than
53% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 1.15 vs. TFX: 2.10 )
TFX' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 2.07
Current: 2.1

0.51
2.07
Earnings Yield (Greenblatt) 4.80
TFX's Earnings Yield (Greenblatt) is ranked higher than
73% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. TFX: 4.80 )
TFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 12.1
Current: 4.8

4.2
12.1
Forward Rate of Return (Yacktman) 2.50
TFX's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. TFX: 2.50 )
TFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 25.7
Current: 2.5

2.9
25.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TBH.Germany
Teleflex Inc. is a Delaware Corporation incorporated in 1943. The Company is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. To achieve this mission, Teleflex is committed to the following: investing in technology and developing its pipeline; leveraging and building its core franchises and distribution channels; attracting, developing and retaining talented employees around the world; and continuing to build financial strength by expanding its margins and maintaining strong cash flow all in an effort to successfully grow its reputation as a solid investment and a profitable, strong employer. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It sells its products to hospitals and healthcare providers in more than 130 countries through a combination of its direct sales force and distributors. The Company's products are used in a wide variety of markets and are not dependent upon any one end-market or procedure. Teleflex is entirely focused on healthcare and operates as a diversified, global medical technology company. It provides a broad-based platform of products, which it categorizes into four groups: Critical Care, Surgical Care, Cardiac Care and OEM and Development Services. It is a provider of specialty products for critical care, which is predominantly comprised of single-use products. The large majority of sales for single-use products are made to the hospital/healthcare provider market, with a smaller percentage sold to alternate sites. The Company's surgical products include: ligation and closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; and fluid management products used for chest drainage. The Company's surgical products also include hand-held instruments for general and specialty surgical procedures. It markets surgical products under the Deknatel, Pleur-evac, Pilling, Taut and Weck brand names. Products in Cardiac Care category include diagnostic catheters and capital equipment. The Company's diagnostic catheters include thermodilution and wedge pressure catheters; specialized angiographic catheters, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures; and intra-aortic balloon, or IAB, catheters. Capital equipment includes its intra-aortic balloon pump, or IABP, consoles. IABP products are used to augment oxygen delivery to the cardiac muscle and reduce the oxygen demand after cardiac surgery, serious heart attack or interventional procedures. The IAB and IABP
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 
Teleflex Inc. Reports Operating Results (10-Q) Jul 23 2010 
Teleflex Inc. Reports Operating Results (10-Q) Apr 28 2010 

More From Other Websites
Teleflex to Present at the 2014 Morgan Stanley Global Healthcare Conference Aug 26 2014
The ARROW® VPS G4™ Device, a Vascular Positioning System from Teleflex, Streamlines Placement of... Aug 25 2014
Teleflex Celebrates 200 Years of the Pilling® Brand in the Surgical Instrument Marketplace Aug 14 2014
TELEFLEX INC Financials Aug 08 2014
Wall Street Transcript Interview with Jay D. Miller, the President and CEO of IMRIS Inc. (IMRS) Aug 01 2014
TELEFLEX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 30 2014
Teleflex Announces Quarterly Dividend Jul 30 2014
Q2 2014 Teleflex Incorporated Earnings Release - Before Market Open Jul 30 2014
Teleflex Reports Second Quarter 2014 Results Jul 30 2014
Teleflex Receives FDA Clearance for 150 cm Length Arrow® GPSCath® Balloon Dilatation Catheters Jul 29 2014
Teleflex Announces European Launch of LMA SureSeal™ PreCurved Jul 28 2014
Teleflex Signs New Agreement with Amerinet for Manual Ligation Products Jul 23 2014
Teleflex Signs New Agreement with Amerinet for Surgical Instruments Jul 23 2014
Teleflex Receives FDA Clearance for ARROW-ClarkTM VectorFlow™ Chronic Hemodialysis Catheter Jul 22 2014
Teleflex Announces Second Quarter 2014 Earnings Conference Call Information Jul 16 2014
Teleflex Showcases the ISO-Gard® Mask with ClearAir™ Technology at Premier, Inc. Breakthroughs... Jul 01 2014
Teleflex to present at World Congress on Vascular Access 2014 (“WoCoVA”) in Berlin Jun 16 2014
Teleflex management to meet with William Blair May 28 2014
Teleflex to present Arrow, LMA, Rusch brand anethesia products May 27 2014
Teleflex to showcase key focus anesthesia products at Euroanesthesia 2014 (“ESA”) in Stockholm May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK